Cumberland Pharmaceuticals (CPIX) vs Upstream Bio (UPB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cumberland Pharmaceuticals (CPIX) has outperformed Upstream Bio (UPB) over the past year, gaining 193.5% versus a loss of 93.8%. Cumberland Pharmaceuticals is the larger company by market cap ($87.6 million vs $87.2 million), about 1.0 times the size, while Upstream Bio is growing revenue faster (+20.4% vs +17.6%). Cumberland Pharmaceuticals converts more of its revenue into profit, with a net margin of -6.4% versus -5026.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CPIX | UPB |
|---|---|---|
| Share price | $5.84 | $1.59 |
| Market cap | $87.57M | $87.15M |
| 1-day change | -7.30% | -20.50% |
| YTD return | +46.73% | -94.14% |
| 1-year return | +193.47% | -93.78% |
| 5-year return | +161.88% | — |
| Forward P/E | 41.71 | — |
| EPS (TTM) | $-0.57 | $-3.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $44.52M | $2.85M |
| Revenue growth (YoY) | +17.57% | +20.42% |
| Net income (latest FY) | $-2.84M | $-143.44M |
| Gross margin | 85.02% | — |
| Operating margin | -6.27% | -5618.82% |
| Net margin | -6.37% | -5026.03% |
| 52-week high | $9.28 | $33.68 |
| 52-week low | $2.00 | $1.56 |
| Distance from 52-week high | -37.07% | -95.28% |
| Analyst consensus | — | buy |
| Avg. price target upside | — | +1245.91% |
| Average volume | 114.52K | 1.01M |
| Shares outstanding | 15.00M | 54.81M |
| Employees | 88 | 75 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CPIX has outperformed UPB by 287.2 percentage points over the past year.
- Cumberland Pharmaceuticals is more profitable, keeping -6.4 cents of every revenue dollar as net income versus -5026.0 cents for Upstream Bio.
About Cumberland Pharmaceuticals
CPIX stock →Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H.
Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees
About Upstream Bio
UPB stock →Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
CPIX vs UPB FAQ
Which is bigger, Cumberland Pharmaceuticals or Upstream Bio?
Cumberland Pharmaceuticals (CPIX) is larger, with a market capitalization of $87.57M compared with $87.15M for Upstream Bio (UPB).
Which stock has performed better over the past year, CPIX or UPB?
CPIX returned +193.47% over the past 12 months, compared with -93.78% for UPB (price return, excluding dividends). Past performance does not predict future results.
Are Cumberland Pharmaceuticals and Upstream Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.